From Nasdaq:

Applied Therapeutics Inc. (APLT) reported mixed results from a Phase 3 trial of AT-001 in patients with Diabetic Cardiomyopathy (DbCM) at high risk for heart failure. The stock closed regular trading at $3.79, up 5.57%, but dropped 28.76% in after-hours trading. The study showed a trend favoring AT-001 in stabilizing or improving cardiac function, but the difference from the placebo group was not statistically significant. AT-001 was generally safe and well tolerated. The company plans to move forward by partnering with focus on the development and regulatory preparations for the govorestat rare disease program. The company also submitted applications for govorestat with regulatory bodies.



Read more: Applied Therapeutics Announces Mixed Results From Phase 3 Trial Of AT-001 In Diabetic Cardiomyopathy